Quick Answer
Tenaya Therapeutics, Inc. reported Net Income Loss of -$90.60 million for the year ending 2025.
- Tenaya Therapeutics, Inc. showed an increase of +18.5% in Net Income Loss from 2024 to 2025.
- This data is from Tenaya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 11, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Tenaya Therapeutics, Inc.'s Net Income Loss has declined by 136.0%.
- Historical annual values: Fiscal year 2025: -$90.60 million | Fiscal year 2024: -$111.13 million | Fiscal year 2023: -$124.08 million | Fiscal year 2022: -$123.67 million | Fiscal year 2021: -$72.72 million | Fiscal year 2020: -$38.40 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: